Panmure Gordon Reiterates Buy Rating for Allergy Therapeutics plc (AGY)
Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reiterated by investment analysts at Panmure Gordon in a research report issued to clients and investors on Monday. They presently have a GBX 53 ($0.66) target price on the stock. Panmure Gordon’s target price suggests a potential upside of 149.41% from the company’s current price.
AGY has been the subject of several other reports. Numis Securities Ltd initiated coverage on Allergy Therapeutics plc in a research note on Wednesday, September 21st. They set a “buy” rating and a GBX 37 ($0.46) target price for the company. Stifel Nicolaus reissued a “buy” rating and set a GBX 72 ($0.89) target price on shares of Allergy Therapeutics plc in a research note on Friday, July 8th.
Shares of Allergy Therapeutics plc (LON:AGY) traded up 6.92% on Monday, hitting GBX 21.25. The stock had a trading volume of 345,231 shares. The company’s market cap is GBX 125.20 million. Allergy Therapeutics plc has a 12-month low of GBX 17.25 and a 12-month high of GBX 34.82. The stock has a 50 day moving average price of GBX 18.88 and a 200-day moving average price of GBX 22.06.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/panmure-gordon-reiterates-buy-rating-for-allergy-therapeutics-plc-agy.html
In other Allergy Therapeutics plc news, insider Peter Jensen purchased 30,000 shares of the firm’s stock in a transaction on Thursday, September 29th. The stock was bought at an average cost of GBX 19 ($0.24) per share, with a total value of £5,700 ($7,054.46). Also, insider Nicolas Wykeman purchased 150,000 shares of the firm’s stock in a transaction on Tuesday, September 27th. The shares were acquired at an average cost of GBX 18 ($0.22) per share, with a total value of £27,000 ($33,415.84).
About Allergy Therapeutics plc
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.